Background
Metastasis is a process by which tumors spread from primary organs to other sites in the body and is the major cause of death for cancer patients. The ovarian cancer G protein-coupled receptor 1 (OGR1) gene has been shown to be expressed at lower levels in metastatic compared with primary prostate cancer tissues.
Methods
We used an orthotopic mouse metastasis model, in which we injected PC3 metastatic human prostate cancer cells stably transfected with empty vector (vector-PC3) or OGR1-expressing vector (OGR1-PC3) into the prostate lobes of athymic or NOD/SCID mice (n = 3-8 mice per group). Migration of PC3 cells tran siently transfected with vector control or with OGR1-or GPR4 (a G protein-coupled receptor with the highest homology to OGR1 (-expressing vectors was measured in vitro by Boyden chamber assays. G pro tein alpha-inhibitory subunit 1 (Gαi1) expression after treatment with pertussis toxin (PTX) was measured using immunoblotting analysis. The inhibitory factor present in the conditioned medium was extracted using organic solvents and analyzed by mass spectrometry.
Results
in vivo, all 26 mice carrying tumors that were derived from vector-PC3 cells developed prostate cancer metastases (mean = 100%, 95% confidence interval [Cl] = 83.97% to 100%) but few (4 of 32) mice carrying tumors derived from OGR1-expressing PC3 cells (mean = 12.50%, 95% Cl = 4.08% to 29.93%) developed metastases. However, exogenous OGR1 overexpression had no effect on primary prostate tumor growth in vivo. In vitro, expression of OGR1, but not GPR4, inhibited ceil migration (mean percentage of cells migrated, 30 .2% versus 100%, difference = 69.8%, 95% Cl = 63.0% to 75.9%; P<.001) via increased expres sion of Gαi1 and the secretion of a chloroform∕methanol-extractable heat-insensitive factor into the condi tioned medium through a PTX-sensitive pathway.
Conclusion
OGR1 is a novel metastasis suppressor gene for prostate cancer. OGR1's constitutive activity via Gαi contributes to its inhibitory effect on cell migration in vitro.
J Natl Cancer Inst 2007;99: Approximately 1.4 million new cancers were diagnosed, and more than 564000 deaths from cancer were expected, in the United States in 2006 (1) . The majority of these cancer-related deaths will be due to tumor metastasis rather than to the primary tumors. Thus, the major clinical challenge is to combat systemic metastatic disease.
Unlike tumor suppressor genes, such as p53 and Rb, metastasis suppressor genes reduce the metastatic propensity of cancer cell lines without substantially affecting their tumorigenesis in vivo (2) (3) (4) . Well-defined metastasis suppressor genes include NM23, MKK4, KAI1, BRMS1, KiSSl, RHOGDI2, CRSP3, and VDUP1 (2, 5, 6) . Metastasis suppressor genes operate at different levels in the metastatic process (2, 3) through mechanisms that involve mitogen-activated protein (MAP) kinase (ERK, p38, and JNK kinases) regulation, integrin interaction, epidermal growth factor desensitization, Gap junction communication, modulation of G protein-coupled receptors or G proteins; they can also function as coactivators of transcription and inhibitors of thioredoxin (2, 3, 5) . Targeting metastasis suppressor genes has high therapeutic poten tial. Although there are many steps in metastasis, blocking only one of these steps may potentially inhibit or prevent metastasis. Moreover, unlike classical tumor suppressor genes, most metasta sis suppressor genes are not mutated in tumor tissues but instead their expression is suppressed by promoter methylation and/or other mechanisms. Thus, restoring metastasis suppressor gene ex pression may be sufficient to suppress tumor metastasis (5, 7) .
Identifying prostate cancer-related metastasis suppressor genes and their mechanisms of action is important for the development of novel strategies for the prevention and treatment of metastatic prostate tumors. An estimated 234460 new cases and 27 350 deaths from prostate cancer were expected in the United States in 2006 (1) . With the introduction of the prostate-specific antigen (PSA) screening test, approximately 75% of prostate cancers are detected when the disease is clinically confined to the prostate. However, in many patients, the cancer often progresses to an androgenindependent metastatic stage for which few treatment options are available. Several metastasis suppressor genes have been identified in prostate cancer, including CD44, NM23, MKK4, and KAI1 (8) .
G proteins and G protein-coupled receptors have important roles in prostate cancer (9) (10) (11) and in other pathologic processes. Of the 100 leading pharmaceutical products developed in 2000, 39 act through a G protein-coupled receptor-mediated mecha nism, underlining the importance of G protein-coupled receptors as important pharmaceutical targets (12) . We have previously cloned OGR1, a G protein-coupled receptor from the HEY hu man ovarian cancer cell line (13) . OGR1 and related subfamily members GPR4, G2A, and TDAG8 mediate the functions of several lysophospholipids, including sphingosylphosphorylcholine (SPC), lysophosphatidylcholine (LPC), and psychosine (14) (15) (16) (17) (18) , which include endothelial barrier function, endothelial cell proliferation, migration, and tube formation, T cell migration, gluco corticoid-induced thymocyte apoptosis, and globoid cell formation.
In addition, all members of the OGR1 subfamily exhibit protonsensing properties (19, 20) . Using small hairpin RNA to inhibit ex pression of GPR4 followed by replenishment with mutant GPR4, we have shown that endogenous GPR4 mediates the proliferation, migration, and tube formation effects of SPC. In addition, unlike ear lier studies in HEK293 cells, for which GPR4 overexpression resulted in increased cAMP production in response to changes in cellular pH (19) , we have shown (15) (21) and can be achieved through various mechanisms (12, (21) (22) (23) .
LaTulippe et al. (24) have conducted a comprehensive gene expression analysis of prostate cancer using oligonucleotide arrays with more than 63 000 probe sets to identify genes and expressed sequences with substantial differential expression between non recurrent primary prostate cancers and metastatic prostate cancers. Interestingly, among the top 100 differentially expressed genes that were identified in this study, OGR1 expression was shown to be fivefold lower in tumor metastases than primary tumors (24) .
In this study, we investigated the role of OGR1 in prostate can cer metastasis using an orthotopic model in athymic (nu∕nu) and nonobese diabetic/severe combined immunodeficiency (NOD/SCID) mice. We also investigated the effects of OGR1 expression on meta static prostate cancer cell migration in vitro and the mechanisms underlying these effects using stable PC3 prostate cancer cell clones.
Materials and Methods

Materials
Male athymic mice (n = 26, 5-7 weeks old; nu∕nu) were obtained from Charles River Laboratories (Wilmington, MA 
Cell Culture
The androgen-independent metastatic human prostate cancer cell line PC3 and the human embryonic kidney 293T (HEK293T) cell line were purchased from American Type Culture Collection (Manassas, VA). The immortalized human microvascular endothelial cell line-1 (HMEC-1) was from the Centers for Disease Control and Prevention (Atlanta, GA). PC3 and HMEC-1 cells were cultured in RPMI-1640. C4-2 and DU145 human prostate cancer cell lines (obtained from Dr Warren Heston at the Cleveland Clinic), and HEK293T cells were cultured in Dulbecco's modified Eagle medium. Media were supplemented with 10% fetal bovine serum (FBS), 100 units/mL penicillin-streptomycin, and 2 mM glutamine. Cells were maintained in a humidified 5% CO2 atmosphere at 37 oC.
Plasmid Construction
The pcDNA3-OGRl (human) and pcDNA3-GPR4 (human) plas mids were generated in our laboratory as described previously (12, (21) (22) (23) 
Postsurgical and Necropsy Procedures
Following tumor cell injection, mice were observed daily for signs of tumor development, including hunched posture, abdominal bloat ing, or loss of mobility. Alice were killed on day 45 when tumors had metastasized to other organs in the control mice by CO2 inhalation, and necropsies were performed to assess tumor growth and metas tasis. Metastases in different organs were measured and counted using fluorescence or light microscopy. All primary prostate tumors and metastases were harvested, fixed in 10% neutral buffered forma lin, embedded in paraffin, sectioned into 5-μm slices, and then either stained with hematoxylin and eosin or immunostained using anti bodies as described below. Bones (ribs, tibia, and femur) from mice injected with control EGFP-PC3 or OGR1-EGFP-PC3 clones were removed, dissected free of most adherent tissues, and observed immediately with epifluorescence microscopy. In addition, bones were fixed in 4% paraformadehyde and decalcified in 14% EDTA (pH 7.4) for 2 weeks at 4 oC. The decalcified bones were sectioned and observed using epifluorescence microscopy.
Microscopy and Reverse Transcription-Polymerase Chain Reaction to Detect Metastases
Tumors expressing EGFP were observed using a Leica fluorescent stereomicroscope equipped with green (fluorescein, 480Ex∕530Em) and red (TexasRed, 560Ex∕630Em) filters (model MZ 16FA To detect potential microscopic tumors, small portions of liver (three to four portions per mouse) were collected from seven to eight mice from each group of EGFP-PC3 or OGR1-EGFP-PC3. Total RNA was isolated, and reverse transcription (RT)-PCR was carried out using primers specific for EGFP and β-actin. The primers for EGFP were 5'-CCT ACG GCG TGC AGT GCT TCA GC-3' (forward) and 5'-CGG CGA GCT GCA CGC TGC GTC CTC-3' (reverse). The primers for β-actin were 5'-AAG GCC AAC CGT GAA AAG ATG ACC-3' (forward) and 5'-ACC GCT CGT TGC CAT TAG TGA TGA-3' (reverse) (GenBank accession number NM_OO7393).
In Vivo Primary Tumor Cell Proliferation Assay
Cell proliferation in primary prostate tumors was assessed using 5-bromo-2-deoxyuridine (BrdU; Sigma) staining. Mice were in jected intraperitoneally with 40 mg/kg body weight of BrdU. After 2 hours, mice were killed as described above, and primary prostate tumors were excised, formalin fixed, and embedded in paraffin (from each primary tumor of seven to eight mice per group).
Immunohistochemistry for OGR1, 5-Bromo-2-Deo×yuridine, and Natural Killer Cells
Immunostaining was performed on primary tumor sections using the Vectastain Universal ABC kit (Vector Laboratories). Briefly, paraffin-embedded tissues were deparaffinized with xylene or Histo-Clear (National Diagnostics, Atlanta, GA) and dehydrated using decreasing gradient alcohol washes (100%, 95%, and 80% ethanol). Antigen retrieval was performed by microwaving the sec tions in 10 mM citrate buffer for 1 minute. Sections were then blocked with horse serum (included in the Vectastain Universal ABC kit) (2.5% in PBS) and incubated overnight with rabbit anti-human OGR1 polyconal antibody (1:500 dilution) or for 30 minutes with rat anti-mouse monoclonal CD49b (NK1.1, 1:250 dilution) or mouse monoclonal anti-BrdU sera (1: 500). Sections were then incubated with biotinylated pan-specific universal secondary antibody (according to the user manual from Vector Laboratories) for 10 minutes, followed by incubation with streptavidin-peroxidase for 5 minutes and 3, 3'-diaminobenzidine. The staining levels in the negative controls (duplicate slides without primary antibodies) were used as background. All cells that stained brown were considered positive. Immunostaining was scored (×20 magnification) on triplicate tissue sections from each group of mice by an independent observer blindly (Dr Weiling Xu).
Terminal Transferase dUTP Nick End Labeling Assay to Detect Cells Undergoing Apoptosis
Terminal transferase dUTP nick end labeling assays were per formed to detect apoptotic cells in the primary tumors by using an Apoptag Peroxidase In Situ Apoptosis Detection Kit (Chemicon, Temecula, CA). Tumor sections (from seven to eight mice per group) were deparaffinzied and rehydrated as mentioned above and then incubated in 20 μg∕mL proteinase K for 15 min utes at room temperature and washed twice with distilled water. Next, the endogenous peroxidase activity in the tumor sections was blocked by incubation for 5 minutes with 3 % H2O2 in PBS, followed by incubation for 10 seconds with equilibration buffer. The sections were then incubated for 1 hour at 37 oC with termi nal deoxynucleotidyl transferase enzyme in reaction buffer (according to the manufacturer's instructions). The reaction was terminated by incubation with stop buffer at room temperature. Sections were then incubated with peroxidase-conjugated antidigoxigenin antibody for 30 minutes, and the reaction was devel oped with diaminobenzidine substrate for 4 minutes at room temperature.
RNA Isolation and RT-PCR to Measure OGR1 and EGFP mRNA Expression
Total RNA was extracted from 5.0 × 105 to 6.0 x 105 OGR1-PC3, vector-PC3, DU145, and C4-2 cells or from 2.5 mg of primary tumors or livers from mice injected with vector-PC3 and OGR1-PC3 clones using the total SV RNA isolation kit (Promega, Madison, WI) following the manufacturer's protocol. First-strand cDNA was synthesized from 2.5 μg DNA-free total RNA using the SuperScript II first-stand synthesis kit (Invitrogen). OGR1 expression levels were analyzed by semi-quantitative RT-PCR. Glyceraldehyde-3-phosphate dehydrogenase served as the loading control. RT-PCR for the OGR1-EGFP fusion protein was performed with an OGR1-specific forward primer (5'-TCCGGGAAAAGCGGGGC-3') and an EGFP-specific reverse primer (5'-TGCAGAAATTCTTACTTGTACAGCTCGTCCA TG-3'). For OGR1, RT-PCR was performed using OGR1-specific forward (5'-CTGCCTGTCCCTCTACTTCG-3') and reverse (5'-TGTTCTCGTACAGGAGGATGC-3') primers. Quantita tive PCR was performed with primers obtained from Gorilla Genomics, Inc (Alameda, CA). The primer sequences for OGR1 were 5'-CACCGTGGTCATCTTCCTG-3' (forward) and 5'-GGAGAAGTGGTAGGCGTTGA-3' (reverse). The β2-microglobulin housekeeping gene (NM_004048) was used as the loading control. The primer sequences used to amplify the β2-microglobulin were 5'-ACTGGTCTTTCTATCTCTTGTACT-3' (forward) and 5'-CTGCTTACATGTCTCGATCC-3' (reverse). Experiments were performed three times in triplicate for each cell line. The primers used for measuring EGFP mRNA in the liver tissues were 5'-GACGACGGCAACTACAAGA-3' (forward) and 5'-GATGCCGTTCTTCTGCTT-3' (reverse). PCR was per formed with RNA isolated from three to four portions of each liver per mouse from 16 mice per group.
Immunoblot for G protein alpha-inhibitory subunit 1
Vector-PC3 and OGR1-PC3 cells (at 80%-85% confluence in a six-well plate) were treated with or without actinomycin D (500 ng/mL Calbiochem, San Diego, CA) for 24 
pH Effect Studies
To test the effect of pH on tire secretion of arachidonic acid (AA) and LPC in OGR1-PC3 cells, physiologic salt solutions (PSS; 130 mM NaCl, 0.9 mM NaH2PO4, 5.4 mM KC1, 0.8 mM MgSO4, 1 mM CaCl2, 25 mM glucose, and 20 mM HEPES) at three different pHs (6.8, 7.4, and 7.8) were prepared (25) . Vector-PC3 and OGR1-PC3 cells were incubated with each of the PSS for 90 minutes in a humidified 5% CO2 atmosphere chamber at 37 oC. Cell superna tants were collected, and AA and LPC were extracted as described below. Five independent experiments were performed in triplicate.
Preparation of Conditioned Media
Vector-PC3 and OGR1-PC3 cells were grown in 10-cm2 tissue culture plates to 85%-95% confluence. The media was then removed, the cells were washed twice with PBS, and serum-free RPMI-1640 medium containing 100 units/mL penicillin-strepto mycin and 2 mM glutamine (6 mL) was added to each plate. The conditioned medium was collected after 12-16 hours of incuba tion and stored at -80 oC in glass or siliconized plastic tubes before analysis. For experiments using pertussis toxin (PTX) treatment, vector-PC3 and/or OGR1-PC3 cells were plated as above and pretreated with 100 nM PTX for 16 hours. The PTX media was removed, and the cells were washed twice with PBS and incubated in either serum-free or complete medium (RPMI-1640 with 10% FBS), and medium was collected as described above. This proce dure was performed three times in triplicate.
Migration Assay
Parental PC3 cells and PC3 clones were cultured to 85%-95% confluence and subjected to serum starvation for 16 hours before assay. Cells were dissociated by incubation with trypsin-EDTA (0.05% trypsin, 53 mM EDTA), washed twice with PBS, and counted using a hemocytometer. The lower side of the insert of the 24-well transwell migration chamber membrane ( 
Transendothelial Migration Assay
A monolayer of HMEC-1 cells was generated on 24- To study the effect of heat-treated conditioned media on paren tal PC3 cell migration, conditioned media from OGR1-PC3, LPC was extracted from the conditioned media from vector-PC3 or EGFP-PC3 and OGR1-PC3 or OGR1-EGFP-PC3 using the method of Bligh and Dyer (26) . In brief, 10 μL of 12:0 LPC (1 μM) was added (as an internal standard, IS) to 1.8 mL condi tioned medium, which was mixed with 3 mL of methanol/chloroform (2 :1). The samples were mixed by vortexing for 1 minute and incubated on ice for 10 minutes. Chloroform (1 mL) was added to separate the phases, and the samples were mixed by vortexing for 1 minute and then centrifuged (1750g for 10 minutes, at 4 °C). The lower phase was transferred to a new glass tube. The upper phase was re-extracted and the lower phases were combined. The experiment was performed at least seven times independently, each in triplicate. Arachidonic acid was extracted using ethyl acetate (27) . In brief, 1 mL of conditioned medium from each sample was mixed with 3 mL of ethyl acetate, and 10 pL of HC1 was added. The samples were vortexed for 1 minute and then centrifuged (1750g for 10 minutes, at 4 °C). The upper phase was transferred to a new glass tube, the solvent was evaporated under nitrogen at room temperature, and the dried lipids were resuspended in 100 pL of methanol for mass spectrometry (MS) analyses.
MS analyses of lipid extracts from conditioned media samples were performed using API-4000 LC-MS-MS (Applied Biosystems∕ MDS SCIEX). Data processing was highly automated using the mass spectrometer software and Excel. Samples (10 pL) were directly delivered into the electrospray ionization source through the LC system (Agilent 1100) with an autosampler. The mobile phase was methanol/water/AmOH (90:10:0.1, vol/vol/vol) with a flow rate of 0.1 mL∕min and 3 minutes for each sample. Quantitative analyses were performed using the methods described previously (28, 29) in the multiple reaction monitoring mode. The peak inten sity ratios (standard/IS) versus the concentration ratios (standard/ IS) were plotted and fitted using linear regression. At least seven independent experiments were performed, each in triplicate.
Statistical Analysis
Data are presented as means with 95% confidence intervals (CIs) of at least three independent experiments. Different values among groups were compared using Student's t test. All statistical tests were two-sided, and P values less than .05 were considered to be statistically significant. (Figs. 1 and 2, G) . However, cells that were transfected with OGR1 expression vectors (OGR1-PC3 or OGR1-EGFP-PC3) overexpressed OGR1 (Fig. 1) . To avoid dif ferential effects resulting from different OGR1 insertion sites across clones, both selected single-cell clones and a pooled clone (a pool of several selected single-cell clones) of PC3 cells were used in subsequent experiments. OGR1 was fused to EGFP to enable easy observation and analysis of PC3-derived primary and meta static tumors using fluorescence microscopy. However, to avoid potential EGFP-related nonspecific effects, we also transfected cells with OGR1 plasmids without the EGFP fusion (OGR1-PC3 clone).
To study the effect of OGR1 on tumoriginesis and metastasis in vivo, we used mouse models of metastatic prostate cancer. Athymic and NOD/SCID mice were randomly divided into two groups (three to eight mice per group), and PC3 clones were injected orthotopically into the prostate gland of each mouse. Forty-five days later, mice were killed and tumor development was examined. Mice that had been injected with vector-PC3 or EGFP-PC3 formed primary tumors in the prostate glands and metastatic tumors in the liver, spleen, kidney, stomach, lung, lymph nodes, diaphragm, and mesentery (Fig. 2 , A-C; arrows indicate tumor loci). In contrast, the mice that were injected with the OGR1-PC3 or OGR1-EGFP-PC3 clones developed tumors that were con fined to the prostate gland and did not metastasize to any of the other organs examined (Fig. 2, A-C) . To rule out a potential nonspecific effect of EGFP, we also tested the effect of OGR1-PC3 (without EGFP fusion) cells in mice, using the vector-PC3 cells as the control.
We conducted four independent sets of experiments (Table 1 ) in athymic and NOD/SCID mice. Overall, we observed a statis tically significant reduction in metastases when exogenous Fig. 2 (continues)   Fig. 2 (Table 1 ). In addition, the metastases in control mice were larger (>2 mm) and often fused together to form tumor aggregates (Fig. 2, A and Table  1 ). We did not observe bone metastases in either the control or the OGR1 mice (data not shown), which is consistent with pre vious reports using the same PC3 injection model (31, 32) . In addition, we tested the potential existence of microscopic tumors using PCR-based detection of EGFP in the liver samples collected from both control (EGFP-PC3) and OGR1 (OGR1-EGFP-PC3) groups. Although EGFP was detected in overt tumors, no EGFP was detected in liver samples that appeared to be tumor free, suggesting the absence of microscopic tumors (Fig. 2, H) .
We obtained similar results in athymic mice and NOD/SCID mice (Fig. 2, B We next compared growth of primary tumors in mice that were injected with either vector control or OGR1-PC3 cells. These mice developed primary prostate tumors that were similar in size, suggesting that OGR1 did not affect primary tumor growth (Fig. 2, A, o and p; Fig. 2 , B, e-h; Fig. 2 , C, c-f; Table 1 ). The fluorescence intensity of the primary tumors in the OGR1 mice appeared lower than that of the control mice (compare Fig. 2 , A, o and p and Fig. 2 , B, e and f). This difference was mainly due to lower EGFP expression in the OGR1-EGFP-PC3 cells compared with that in EGFP-PC3 cells (Fig. 2, B and D) .
To further evaluate the effect of OGR1 overexpression on pri mary tumor cell proliferation, we conducted BrdU incorporation and terminal transferase dUTP nick-end labeling assays in xeno graft tumors from the athymic or the NOD/SCID mice. We observed that primary prostate tumors derived from vector control and OGR1-PC3 cells had similar BrdU incorporation (Fig. 2, E) . Minimal apoptosis was detected in tumor sections derived from both control and OGR1-expressing cells (Fig. 2, F) , confirming that OGR1 did not affect growth and apoptosis of the primary tumors.
Thus, by the definition of metastasis suppressor gene (3, 7) , our data support the hypothesis that OGR1 is a novel metastasis sup pressor gene in prostate cancer. We also confirmed that tumors derived from OGR1-PC3 cells still expressed OGR1 as assessed by immunohistochemical staining (Fig. 2, G) . (Fig. 3, A and B) . We also conducted transendothelial migration assays to mimic the intravasation process in vivo and found that OGR1 also inhibited this activity to a similar extent (70% inhibition) (Fig. 3, C) . In addition, we performed cell migra tion assays with C4-2 and DU145 prostate cancer cell lines (which do not express endogenous OGR1, as assessed by PCR; data not shown) and found that OGR1 statistically significantly inhibited migration in both cell types similar to that of PC3 cells (70% reduc tion in migration, P<.001 for both C2-4 and DU145) (Fig. 4, A) , suggesting that OGR1 s inhibitory effect on cell migration is not limited to PC3 cells. Fig. 3 . The effect of ovarian cancer G proteincoupled receptor 1 (OGR1) in cell migration to vitronectin and the involvement of G protein alpha-inhibitory subunit 1. Migratory properties of vector-and OGR1-PC3 cells to vitronectin were assessed using transwell assays. Stably trans fected vector control-PC3 or OGR1-PC3 cells were serum starved for 16 hours. Cells (1 × 105) in 300 μL of serum-free RPMI were added to the upper chamber of a vitronectin-coated transwell, and 300 μL of serum-free RPMI was added in the lower chamber. A) Cell migration of control (CONT, vector-PC3 or EGFP-PC3) and two stable clones of OGR1-PC3 cells (OGR1#1;OGR1-PC3, and OGR1#2; OGR1-EGFP-PC3) and GPR4-PC3 (GPR4) are shown. To compare effects of OGR1 and GPR4, cells were transiently transfected with OGR1 and GPR4 expression vectors or empty pcDNA3 vector as control and serum starved, and migration assays were conducted 48 hours after transfec tion. B and C) Cell migration [transwell (B) and transendothelial (C)] in OGR1-PC3 cells compared with parental or vector-PC3 cells (***P<.001). Rvalues were calculated using two-sided Student's t test). More than 10 independent experiments were performed in triplicate. Fig. 3 . B) Effects of treatment with pertussis toxin (PTX) (100 ng∕mL) for 16 hours or transfection (1.5 μg of DNA per six-well plate) with a dominant-negative (DN-) form of G protein alpha-inhibitory subunit 1 (Gαi1) on the inhibition of OGR1-PC3 cells migration. In A and B, mean (and 95% confidence intervals) percentages of migrated cells (result from four independent experi ments in triplicate) are shown. P values (two-sided) were calculated using Student's t test. C) lmmunoblotting was performed to test the effect of OGR1 on the expression of Gαi1 protein level in two pairs of the control and the OGR1 cell lines in the absence (pair #1; vector-PC3 and OGR1-PC3 and #2; EGFP-PC3 and OGR1-EGFP-PC3) or in the pres ence of actinomycin D (pair#2 + ActD). The membrane was reprobed for β-actin to check for equal loading. One representative blot from three independent experiments is shown.
To explore the mechanism of this inhibition, we tested the effect of PTX on the cell migration of vector-and OGR1-PC3 cells. PTX pretreatment stimulated cell migration of OGR1-PC3 cells but had no effect on vector-PC3 cells, suggesting that activating Gαi proteins, which are sensitive to PTX, are involved in OGR1-induced inhibition of cell migration. To confirm this result, cells were transfected with a dominant-negative form of Gαil and cell migration was monitored as before. The dominant-negative form of Gαil reversed the effect of OGR1 (Fig. 4, B) , similar to that seen with PTX, confirming the involvement of a Gαil protein in OGR1's inhibitory effect. Because migration is a critical step in tumor metastasis, the reduced cell migration in vitro may be related to the reduced tumor metastasis that was observed in vivo. To explore how OGR1 regulates Gαil, we tested whether OGR1 expression alters Gαil protein expression. In two pairs of control and OGR1-overexpressing cell lines (pair #1; vector-PC3 and OGR1-PC3 and #2; EGFP-PC3 and OGR1-EGFP-PC3), OGR1 expression increased the expression of Gαil protein, which was blocked by actinomycin D treatment, suggesting that the regula tion was at the transcriptional level (Fig. 4, C) .
To determine whether OGR1 affects cell proliferation in vitro, we conducted cell proliferation assays (both cell number count and MTT assays) in the presence (2% FBS) or absence of growth stimulation (0% FBS). Cells from different clones (vector-PC3 and OGR1-PC3) were incubated in serum-free media, and cell prolif eration was determined after 24, 48, and 72 hours. Similar to what was observed in vivo, OGR1 expression did not affect cell prolifer ation (Fig. 5) . These results suggest that the in vitro behavior of the cells may reflect, at least in part, their in vivo properties and, thus, that some of their signaling mechanisms can be studied in vitro. 
Secretion of an Antimigratory Factor Induced by 0GR1
To test whether OGR1's inhibitory effect on cell migration is mediated by the secretion of a soluble factor, conditioned media was collected front vector-PC3 and OGR1-PC3 cells. Parental PC3 cells were then treated with this conditioned media and subjected to cell migration assays. Conditioned media from the OGR1-PC3 cells, but not vector-PC3 cells, inhibited the migra tion (mean percentage of cells migrated, 36.1% versus 100%, dif ference = 63.9%, 95% CI = 60.8% to 67.1%; P<.001) of parental PC3 cells (Fig. 6, A) . The extent of this inhibition (60%-65%) is similar to that measured in the OGR1-PC3 cell migration assays (~70%). Collectively, these results suggest that a soluble factor(s) secreted into the conditioned media derived from OGR1-PC3 cells is responsible for the majority of the inhibitory effect on tumor cell migration (Fig. 3) . To determine whether the conditioned media was required during cell migration or whether a short incubation time was sufficient for successful suppression, the parental cells were pre-incubated in conditioned media for 30 minutes. The conditioned media was then removed by centrifugation, and the cells were resuspended in serum-free media before cell migration assays were performed. The inhibitory effect of the conditioned media was lost when the conditioned media was removed before the cell migration assay (Fig. 6, A) , suggesting that a longer prein cubation time or the presence of the inhibitory factor during the cell migration is necessary.
As the first step to identify the nature of this soluble factor, the conditioned media from OGR1-PC3 cells was heated to 95 oC for 30 minutes before migration assays were performed using paren tal PC3 cells. After heating, the conditioned media retained its antimigratory activity (Fig. 6, A Fig. 6, C) , suggesting that Gαi pro tein activity is necessary for secretion of the inhibitory factor.
Because control cells (vector-PC3 or EGFP-PC3) did not secrete a stimulatory factor in their conditioned media (Fig. 6, B) , it is likely that OGR1 expression enhances secretion of an inhibitory factor(s) instead of inhibiting secretion of a stimulatory factor. Thus, we expected to observe an increased amount of a hydrophobic factor in conditioned media from OGR1-PC3 cells compared with condi tioned media from control cells. AA and LPC are the two major products of phospholipase A, (PLA2) enzymes, and some of LPC's biologic activities may be mediated by the OGR1 subfamily of G protein-coupled receptors (14, 33, 34) . However, we found that OGR1 expression did not increase secretion of either AA or LPC into the media at physiologic pH (7.4) (Fig. 7, C and D) . Therefore, AA and LPC are unlikely to be involved in the inhibitory effect on migration. We also compared other positively or negatively charged ions in the range of 100-1000 kDa from the solvent extracts from the conditioned media from the control versus OGR1 samples using MS (data not shown). No molecular species were consistently increased in the lipids extracts from OGR1-PC3 cells. 
Effects of SPC or OGR1's Proton-Sensing Activities on the OGR1 Antimigratory Phenotype
We and others have observed that OGR1 has constitutive activity (15, 35, 36) . The in vivo and in vitro effects of OGR1 presented above were measured in the absence of exogenous stimuli (other than ECM proteins) and with a constant extracellular pH. Therefore, the activities measured are likely to be mediated through the con stitutive activation of OGR1.
To determine whether SPC influences the inhibitory effect of OGR1 on cell migration, we treated vector-and OGR1-PC3 cells with SPC (1 μM). SPC itself had an inhibitory effect on cell migration (Fig. 7, A) that was not affected by OGR1 expression. OGR1 has also been shown to have proton-sensing activity dur ing inositol phosphate formation in the human embryonic kidney HEK293 and other cell types (20, 25) . In our experiments, the pH of the media was not changed, and therefore, it was unlikely that the proton-sensing activity of OGR1 is involved in OGRl's effect on cell migration. To further address this issue, we constructed an OGR1 mutant (OGR1-H245F) that has impaired proton-sensing ability (25) . OGR1 H245F showed a similar inhibitory effect on cell migration as wild-type OGR1 (Fig. 7, B ). Furthermore, we tested the effect of pH on AA and LPC secretion related to OGR1 expression and found that OGR1 expression did not affect AA and LPC production or secretion at any of the pHs tested (Fig. 7, C) .
Discussion
Metastasis suppressor genes are a class of genes that reduce the metastatic propensity of cancer cell lines in vivo without affecting their tumorigenesis (2) (3) (4) . In this article, we presented the follow ing evidence to support the hypothesis that OGR1 is a novel metastasis suppressor gene in prostate cancer: 1) when OGR1 was overexpressed in PC 3 cells, it suppressed tumor cell metastasis in an orthotopic mouse model of prostate cancer; 2) OGR1 did not affect primary tumor growth, as assessed by the size of the primary tumors and by BrdU incorporation assays; and 3) in vitro, OGR1 expression reduced cell migration, an important step in metastasis, without affecting cell proliferation. These data, together with a previous report showing that OGR1 expression is reduced in meta static compared with primary prostatic tumors (24) , support the hypothesis that OGR1 may have an important role in the metastasis of prostate cancer cells.
OGR1 has been shown to suppress tumor cell growth in ovar ian cancer cells (36, 37) . When OGR1 was expressed fourfold to 10-fold above basal levels in PC3 cells, it did not affect cell growth. GPR4, a G protein-coupled receptor sharing more than 50% homology with OGR1, did not inhibit cell migration, sug gesting a specific antimigratory role for OGR1. These results are consistent with an earlier report showing that GPR4 is oncogenic (38) .
OGR1 has been shown to have a proton-sensing activity (17, 25 ) that may be cell-type and signaling pathway specific (15, 25) . Because an acidic extracellular pH-a characteristic of the microenvironment of solid tumors-has been shown to enhance tumor metastatic potential (39), we have addressed the potential role of the proton-sensing ability of OGR1 in our assays. An OGR1 mutant (H245F) with minimal proton-sensing activity in inositol phosphate accumulation had the same effect as wild-type OGR1 on PC3 cell migration. Furthermore, OGR1 does not affect AA or LPC secretion at different pHs as compared with the control. In addition, OGRl's proton sensing activity is mediated by a Gαq protein (40) . We have observed that a dominant-negative Gαq had no effect on OGRl's effect on cell migration (data not shown) and Gαil mediates the OGRl's effect.
OGR1 and related G protein-coupled receptors may have dual functions for mediating signals from either lipids or protons (19, 20, 41) . SPC, a bioactive lipid molecule, is able to modulate the proton-sensing activity of OGR1. In Chinese hamster ovary cells, SPC inhibits the acid-induced actions in a pH-dependent manner (42) . We tested the effect of SPC on migration of PC3 cells and found that it was inhibitory. However, this inhibitory effect appeared to be independent of OGR1 expression. We cannot com pletely rule out that SPC may have an effect in vivo. These issues warrant further studies. Together, our data suggest that the in vitro effects of OGR1 described in this article are unlikely to be related to SPC or proton sensing and are constitutive in nature.
The mechanisms of OGRl's inhibitory effect on cell migration appeared to be related to Gαil protein activation. G proteincoupled receptor constitutive activity can induce G protein activation. Interestingly, prostate cancer cells express relatively low levels of Gαi proteins, which may have an important regulatory role in cell proliferation and neoplastic transformation in these cells (43) . In addition, immunoblot analysis shows that although the levels of β subunits of G proteins are maintained, those of αs and αi subunits are decreased 30%-40% after neoplastic transfor mation (43) . We showed here that OGR1 expression increased Gαil expression in PC3 cells and that this increase was likely to be at the transcriptional level.
Gi protein activation is involved in the stimulation of cell migration and in intracellular signaling through receptors for lysophosphatidic acid and sphingosine-1-phosphate (44) (45) (46) (47) . In contrast, Gi protein-mediated inhibition of cell migration is much less explored. Nevertheless, it has been shown that a Gi-mediated inhibition of cAMP accumulation is involved in the inhibitory effect of angiopeptin on the migration of vascular smooth muscle cells (48) .
The present study has several limitations. Only one prostate cancer cell line was used in the in vivo models. OGRl's function in additional prostate cell lines should be tested in vivo. Bone metastasis is a major issue for human prostate cancer. The role of OGR1 in bone metastasis has not been assessed because we did not observe bone metastases in either the control or the OGR1 mice. This issue should be tested in different prostate cancer models. In addition, we have not identified the soluble factor that is responsible for the inhibitory effect of OGR1 on cell migration. It is possible that the migration inhibitory factor is present at lower concentrations and thus difficult to detect. It is also possible that the size or charge of the molecule is outside the detection range that we chose. Further studies are required to identify this factor. Nevertheless, our results do suggest that Gi protein activa tion is involved in the secretion of this OGR1-induced inhibitory factor.
Our results show that OGR1 suppresses prostate cancer metas tasis without affecting primary tumor progression, suggesting that OGR1 is a novel metastasis suppressor gene for prostate cancer. Activation of Gil and the secretion of a hydrophobic factor appear to be important for OGRl's antimetastatic action. Further investi gation needs to be conducted to identify the soluble factor(s) involved in this process.
